SyntheticMR Secures Capital for Global AI Neurodiagnostics Expansion Amidst Strong Q4 Revenue Surge
January 22, 2026, 3:38 am
SyntheticMR AB launches a SEK 32.8 million rights issue. Shareholders approved the capital raise. This funding fuels strategic growth. Preliminary Q4 2025 financials reveal a 43% revenue surge. The company leverages its Combinostics acquisition for AI neurodiagnostics expansion. New agreements strengthen recurring revenue streams. Key regulatory milestones include European approval for cNeuro cMRI's ARIA monitoring in Alzheimer's treatment. Indian market access for cMRI is secured. The subscription period for new shares runs from January 20 to February 3, 2026. This capital injection targets sustained global presence and a return to profitability for the medical technology firm. Investors are urged to consult the official information document.
SyntheticMR AB is driving forward with a significant capital raise. The company initiated a new share offering. This rights issue targets approximately SEK 32.8 million. It represents a crucial step. The Board of Directors initially resolved the plan. Shareholders subsequently approved it. An extraordinary general meeting on January 9, 2026, confirmed the decision. This capital infusion is paramount. It aims to fortify SyntheticMR's financial foundations. It will also finance critical strategic initiatives. The overarching objective remains a definitive return to sustainable profitability.
The capital increase coincides with positive operational indicators. SyntheticMR recently disclosed preliminary financial results. These unaudited figures cover the fourth quarter of 2025. They highlight robust performance. Net revenue for Q4 2025 reached MSEK 18.0. This marks a substantial 43 percent increase. The growth compares to MSEK 12.6 in Q4 2024. Full-year 2025 net revenue totaled MSEK 57.0. This signifies a 2 percent rise over the full year 2024. Operating profit (EBIT) showed improvement but remained negative. Q4 2025 EBIT was MSEK -5.3. This compares favorably to MSEK -7.5 in the prior year. However, full-year EBIT registered MSEK -49.3. This figure includes significant impairments. Operating items faced an MSEK -18.5 impairment. Acquisition costs added another MSEK -0.3. Adjusted operating profit for 2025 stood at MSEK -30.5. The company's cash and cash equivalents ended 2025 at MSEK 7.4. This marks a decrease from MSEK 51.0 at the end of 2024. The prior year's balance included a short-term loan for the Combinostics acquisition. That loan has since been repaid.
SyntheticMR's strategic vision emphasizes expansion and recurring revenue. The successful integration of Combinostics is a key achievement. This acquisition significantly broadened SyntheticMR's product portfolio. It solidified its standing in AI-based neurodiagnostics. Organic growth, excluding Combinostics, demonstrated strength. It reached 14 percent during Q4 2025. This growth aligns precisely with previous company forecasts. The focus on recurring revenues is central. SyntheticMR’s cNeuro offering epitomizes this model. Annual Recurring Revenue (ARR) for cNeuro grew 2 percent in Q4. This increase was sequential. Longer sales cycles influenced the quarterly pace. Yet, customer interest remains high. The preliminary ARR value reached MSEK 11.7 by year-end 2025. This translates to an impressive 38 percent full-year growth. Churn rates continue to be low. This underscores the business model's inherent stability and attractiveness.
Market penetration is accelerating through strategic agreements. SyntheticMR secured a significant cNeuro agreement. This partnership is valued at MSEK 1 annually. It involves a key reference customer. Another crucial deal emerged. A five-year SyMRI agreement was inked. It is with one of Europe's premier university hospitals. This contract holds a total value of MSEK 3. These partnerships substantially enhance SyntheticMR's international market presence. However, challenges persist. SyMRI research sales within the United States market face ongoing headwinds. The company is actively optimizing its resources. It balances dedicated efforts between research activities and clinical sales.
Product innovation is delivering competitive advantages. SyntheticMR achieved critical regulatory milestones. The updated cNeuro® cMRI platform gained European regulatory approval. This version incorporates automated ARIA monitoring functionality. It is designed for Alzheimer’s disease treatment. This addresses a rapidly expanding clinical need. New anti-amyloid therapies are entering the market. This approval strategically positions SyntheticMR in a dynamic, expansive market segment. Concurrently, cNeuro® cMRI has been launched in the Indian market. This initiative builds on SyntheticMR's established SyMRI presence. It unlocks a substantial new growth region for the company. These approvals underscore the company's commitment to cutting-edge medical technology.
The rights issue follows a clearly defined schedule. The extraordinary general meeting approved the board's resolution on January 9, 2026. The record date for participation in the offering was January 16, 2026. Comprehensive financial guidance, based on preliminary figures, was released on January 19, 2026. Concurrently, the official information document was published. Trading in subscription rights commenced on January 20, 2026. It will conclude on January 29, 2026. The subscription period for new shares also opened on January 20, 2026. It extends through February 3, 2026. Trading in paid subscribed shares (BTA) began on January 20, 2026. This trading continues until the full registration of the rights issue. The company anticipates publishing the outcome of the offering on February 4, 2026.
Prospective investors should carefully review the information document. It provides full details on the offering's terms. The subscription price stands at SEK 1.10 per share. A full subscription could inject SEK 32,755,076.20 into the company. Existing shareholders receive one subscription right for each share held. Two such subscription rights entitle the holder to subscribe for one new share. The information document is publicly available on SyntheticMR's corporate website. Expert advisors supported the entire process. Sedermera Corporate Finance served as financial advisor. Foyen Advokatfirma provided legal counsel. Nordic Issuing AB acted as the issuing agent.
This capital raise is a strategic imperative. It aims to empower SyntheticMR's ambitious growth agenda. The company's objectives are clear. It seeks to solidify its market position. It prioritizes expanding its base of recurring revenues. Building a robust, scalable global presence remains a core goal. The increasing worldwide demand for advanced MR analysis and neurodiagnostics offers favorable market dynamics. SyntheticMR believes it is optimally positioned. These conditions foster long-term, sustainable growth. The current rights issue, combined with vigilant cost controls, reinforces this trajectory. It provides essential resources for strategic initiatives. It paves a clear path toward sustained profitability. SyntheticMR enters 2026 with an enhanced market posture. Expanded regulatory approvals and solid commercial establishments define its forward outlook. The company's pipeline of new business opportunities remains robust.
SyntheticMR AB is driving forward with a significant capital raise. The company initiated a new share offering. This rights issue targets approximately SEK 32.8 million. It represents a crucial step. The Board of Directors initially resolved the plan. Shareholders subsequently approved it. An extraordinary general meeting on January 9, 2026, confirmed the decision. This capital infusion is paramount. It aims to fortify SyntheticMR's financial foundations. It will also finance critical strategic initiatives. The overarching objective remains a definitive return to sustainable profitability.
The capital increase coincides with positive operational indicators. SyntheticMR recently disclosed preliminary financial results. These unaudited figures cover the fourth quarter of 2025. They highlight robust performance. Net revenue for Q4 2025 reached MSEK 18.0. This marks a substantial 43 percent increase. The growth compares to MSEK 12.6 in Q4 2024. Full-year 2025 net revenue totaled MSEK 57.0. This signifies a 2 percent rise over the full year 2024. Operating profit (EBIT) showed improvement but remained negative. Q4 2025 EBIT was MSEK -5.3. This compares favorably to MSEK -7.5 in the prior year. However, full-year EBIT registered MSEK -49.3. This figure includes significant impairments. Operating items faced an MSEK -18.5 impairment. Acquisition costs added another MSEK -0.3. Adjusted operating profit for 2025 stood at MSEK -30.5. The company's cash and cash equivalents ended 2025 at MSEK 7.4. This marks a decrease from MSEK 51.0 at the end of 2024. The prior year's balance included a short-term loan for the Combinostics acquisition. That loan has since been repaid.
SyntheticMR's strategic vision emphasizes expansion and recurring revenue. The successful integration of Combinostics is a key achievement. This acquisition significantly broadened SyntheticMR's product portfolio. It solidified its standing in AI-based neurodiagnostics. Organic growth, excluding Combinostics, demonstrated strength. It reached 14 percent during Q4 2025. This growth aligns precisely with previous company forecasts. The focus on recurring revenues is central. SyntheticMR’s cNeuro offering epitomizes this model. Annual Recurring Revenue (ARR) for cNeuro grew 2 percent in Q4. This increase was sequential. Longer sales cycles influenced the quarterly pace. Yet, customer interest remains high. The preliminary ARR value reached MSEK 11.7 by year-end 2025. This translates to an impressive 38 percent full-year growth. Churn rates continue to be low. This underscores the business model's inherent stability and attractiveness.
Market penetration is accelerating through strategic agreements. SyntheticMR secured a significant cNeuro agreement. This partnership is valued at MSEK 1 annually. It involves a key reference customer. Another crucial deal emerged. A five-year SyMRI agreement was inked. It is with one of Europe's premier university hospitals. This contract holds a total value of MSEK 3. These partnerships substantially enhance SyntheticMR's international market presence. However, challenges persist. SyMRI research sales within the United States market face ongoing headwinds. The company is actively optimizing its resources. It balances dedicated efforts between research activities and clinical sales.
Product innovation is delivering competitive advantages. SyntheticMR achieved critical regulatory milestones. The updated cNeuro® cMRI platform gained European regulatory approval. This version incorporates automated ARIA monitoring functionality. It is designed for Alzheimer’s disease treatment. This addresses a rapidly expanding clinical need. New anti-amyloid therapies are entering the market. This approval strategically positions SyntheticMR in a dynamic, expansive market segment. Concurrently, cNeuro® cMRI has been launched in the Indian market. This initiative builds on SyntheticMR's established SyMRI presence. It unlocks a substantial new growth region for the company. These approvals underscore the company's commitment to cutting-edge medical technology.
The rights issue follows a clearly defined schedule. The extraordinary general meeting approved the board's resolution on January 9, 2026. The record date for participation in the offering was January 16, 2026. Comprehensive financial guidance, based on preliminary figures, was released on January 19, 2026. Concurrently, the official information document was published. Trading in subscription rights commenced on January 20, 2026. It will conclude on January 29, 2026. The subscription period for new shares also opened on January 20, 2026. It extends through February 3, 2026. Trading in paid subscribed shares (BTA) began on January 20, 2026. This trading continues until the full registration of the rights issue. The company anticipates publishing the outcome of the offering on February 4, 2026.
Prospective investors should carefully review the information document. It provides full details on the offering's terms. The subscription price stands at SEK 1.10 per share. A full subscription could inject SEK 32,755,076.20 into the company. Existing shareholders receive one subscription right for each share held. Two such subscription rights entitle the holder to subscribe for one new share. The information document is publicly available on SyntheticMR's corporate website. Expert advisors supported the entire process. Sedermera Corporate Finance served as financial advisor. Foyen Advokatfirma provided legal counsel. Nordic Issuing AB acted as the issuing agent.
This capital raise is a strategic imperative. It aims to empower SyntheticMR's ambitious growth agenda. The company's objectives are clear. It seeks to solidify its market position. It prioritizes expanding its base of recurring revenues. Building a robust, scalable global presence remains a core goal. The increasing worldwide demand for advanced MR analysis and neurodiagnostics offers favorable market dynamics. SyntheticMR believes it is optimally positioned. These conditions foster long-term, sustainable growth. The current rights issue, combined with vigilant cost controls, reinforces this trajectory. It provides essential resources for strategic initiatives. It paves a clear path toward sustained profitability. SyntheticMR enters 2026 with an enhanced market posture. Expanded regulatory approvals and solid commercial establishments define its forward outlook. The company's pipeline of new business opportunities remains robust.